Misonix Announces Entry Into Surgical Wound Debridement
FARMINGDALE, N.Y., Aug. 10, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications, has announced its immediate entry into surgical wound debridement by adding their SonicOne® technology to the BoneScalpel™ surgical platform. The BoneScalpel with SonicOne Technology is designed for surgical wound debridement and is an updated and expanded version of the Company's existing BoneScalpel product. The SonicOne Wound Debridement System has been marketed by the Company to free-standing wound clinics, hospital-based wound clinics, and long term acute care hospitals for several years.
Misonix's has completed product training with its domestic sales force on the BoneScalpel with SonicOne Technology; training of its international distributors is scheduled on a country by country basis over the next several months. Reimbursement is available for surgical debridement in the U.S. market. The Company's strategy is to market a range of products to effect a complete wound healing protocol for surgery. The BoneScalpel with SonicOne Technology is a companion product to the recently announced Hyalomatrix® skin substitute and will be positioned accordingly.
Wound cleansing and debridement procedures done in the Operating Room include trauma cases, burns, and chronic wound cases that have escalated beyond the capabilities of the wound clinic. In concert with the release of the BoneScalpel with SonicOne Technology, the Company has also begun marketing a comprehensive line of specialty disposables.
The stand-alone SonicOne is an innovative, ultrasonic wound care system that offers tissu